The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan. In addition, the effects of rifampicin on the glucuronidation of bilirubin, an endogenous UDP-glucuronosyltransferase family 1 member A1 (UGT1A1) substrate, were explored.
Introduction
Rifampicin (RIF; also known as rifampin) is an established antibiotic drug, which is known to induce various drugmetabolizing enzymes. Its impact on cytochrome P450 (CYP) enzymes -and on CYP3A4 in particular -has been extensively studied since early reports of drug-drug interactions (DDIs) started emerging in the 1960-1970s (e.g. [1] . In the latest (2017) US Food and Drug Administration draft guidance on clinical DDI studies [2] , RIF is listed as an index inducer of CYP3A4 (and other CYP enzymes) -i.e. as a drug that 'predictably induces metabolism via a given pathway'. Relatively recently, it has been suggested that RIF is not only a CYP3A4 inducer, but also a competitive CYP3A4 inhibitor [3] -a feature that should be taken into account when planning DDI studies with RIF that aim at capturing maximum CYP3A4-mediated interaction effects.
Vilaprisan (VPR) is a selective progesterone receptor modulator (SPRM) [4] [5] [6] [7] , which is currently being tested in phase III clinical trials for the long-term treatment of patients with uterine fibroids. The pharmacokinetic (PK) properties of VPR have been well characterized, as described by SchultzeMosgau et al. [8, 9] . The dominant compound in the plasma after oral administration of the drug is unchanged VPR. Excretion occurs predominantly in metabolized form via the faeces. In vitro data suggest that the clearance of VPR is mediated by CYP3A4 (oxidation) and by aldoketoreductases (AKRs) (reduction) (data on file at Bayer AG, Berlin). The key role of CYP3A4 in the metabolism of VPR was confirmed in a DDI study with itraconazole, a strong CYP3A4 inhibitor [9] . After coadministration of itraconazole, a sixfold higher exposure to VPR was observed than after administration of VPR alone [9] . In view of this finding, we conducted this second DDI study to quantify the effect of a strong CYP3A4 inducer, RIF, as well. As an internal reference and to confirm that treatment with RIF led to CYP3A4 induction in all subjects, we administered a subtherapeutic dose of midazolam (MDZ) together with VPR. MDZ is a sensitive CYP3A4 substrate, which is well characterized and recommended as a marker [10] or index substrate [2] to monitor CYP3A4 induction.
The study design -in particular, the dosing schedule for RIF to achieve maximum induction of CYP3A4 and ensure maximum observable effects, as well as the choice of the lowest MDZ dose that was still sufficient for exposure measurements -was optimized by using a physiologically based PK (PBPK) model, as described by Frechen et al. [11] . It was predicted that coadministration of RIF according to our modelguided dosing schedule would decrease the exposure to VPR by approximately 96% [11] .
Fewer data are available for studies using RIF for the induction of UDP-glucuronosyltransferases (UGTs) than for studies using RIF for induction of CYP enzymes. This is probably related to the eminent importance of CYP3A4 in drug metabolism. However, glucuronidation is essential for the elimination of numerous substances -among them β-oestradiol and the endogenous UGT family 1 member A1 (UGT1A1) substrate bilirubin [12] . Thus, the question arose of whether our dosing schedule -which was developed to optimize the induction of CYP3A4 -might also be suitable to detect an effect of RIF on UGT1A1 substrates. The current understanding about the effect of UGT1A1 induction by RIF is less established, and therefore the present study was used, beside its primary objective regarding CYP3A4, to collect further knowledge on UGT1A1 induction. The endogenous bile acid derivative bilirubin is primarily conjugated by UGT1A1 [13] , and mutations in the UGT1A1 gene that result in decreased activity of the UGT1A1 enzyme are associated with liver disorders such as Gilbert's syndrome (mild unconjugated hyperbilirubinaemia) and the more severe Crigler-Najjar syndrome [13] . Therefore, we monitored changes in the glucuronidation of bilirubin during and after administration of RIF. We hypothesized that the ratio of the conjugated (glucuronidated) to unconjugated bilirubin concentration ('conjugation ratio') would increase during treatment with RIF.
Methods
The study was approved by the relevant independent ethics committee (Ethics Committee of the Landesamt fuer Gesundheit und Soziales, Berlin). All subjects gave their written informed consent before entry into the study. The study conformed to the ethical standards of the 1964 Helsinki Declaration and its later amendments, and the standards of Good Clinical Practice.
Design and treatments
The study was designed as an open-label, single-centre, single-group, fixed-treatment-sequence study in 12 healthy volunteers. It comprised four periods: screening, treatment period 1 (reference), treatment period 2 and a follow-up period ( Figure 1 ). Each treatment period included an in-house stay of 3 days. Screening for eligibility took place within 6 weeks prior to the first drug administration. A follow-up examination took place within 14 days after the last administration of RIF.
PBPK modelling informed the choice of the study design with regard to the expected effect size, the expected variability, an optimized sampling scheme and an optimized dosage regimen [11] . In particular, simulations showed that at least an 8-h time difference between the VPR dose and the next RIF dose would be suitable to mitigate any competitive inhibitory effects on CYP3A4 activity by RIF and thus would show a maximum interaction potential with regard to CYP3A4 induction. In period 1, subjects received a single dose of VPR 1 4 mg plus MDZ 2 1 mg. In period 2, they received RIF 3 600 mg once daily for 11 days; on the eighth day of RIFadministration, they received a second dose of VPR 4 mg plus MDZ 1 mg. The washout period between the two VPR + MDZ doses was at least 14 days, covering more than five elimination half-lives of VPR to secure complete elimination. After administration of VPR + MDZ, RIF was administered for another 3 days, to maintain CYP3A4 activity at the maximum level for the period for which VPR might be measurable. Medications were taken orally under the supervision of study personnel -generally, in the morning, except for the eighth dose of RIF, which was taken in the evening, 12 h after intake of VPR + MDZ, to avoid transient CYP3A4 inhibition by RIF. Both VPR and MDZ were taken on an empty stomach, while RIF was taken 30 min after a light meal. Intake with a light meal improves the gastrointestinal tolerability of RIF without reducing its efficacy significantly [14] . (Intake with a high-fat meal reduces the area under the plasma concentration-time curve from zero to infinity (AUC) of RIF by 6%, to 23% [14] ). Starting the sequence with RIF treatment in a randomized design would have needed a considerably longer washout period to ensure that enzyme activity had returned to normal after intake of RIF. For the objective of the present study, a fixed-sequence design was considered appropriate as potential period effects were expected to be minor and not to affect the overall assessment. The use of prior or concomitant medication expected to have an impact on the study objectives was not permitted. The same applied to foods and beverages (e.g. grapefruit products).
Subjects
Healthy postmenopausal women, aged between 45 years and 65 years (inclusive) and with a body mass index of ≥20 kg m -2 and ≤32 kg m -2 , were eligible for participation. Subjects' postmenopausal status was assessed based on medical history (natural menopause or bilateral ovariectomy at least 12 months or 3 months, respectively, before the first dose). Additionally, plasma levels of follicle stimulating hormone (FSH) had to be >40 IU l À1 , and of oestradiol ≤20 pg ml À1 in women below 60 years of age. Specific exclusion criteria were laid down to exclude subjects with conditions expected to have an impact on the aims of the study. Screening for eligibility also included a gynaecological examination.
Study assessments and variables
Blood samples for PK profiles of VPR, MDZ, and 1 0 -hydroxymidazolam (1'-OH-MDZ), its primary metabolite mediated by CYP3A4, were taken predose and 0.5, 1, 1.5, 2, 2. Overall study design. Screening took place within 6 weeks before the first dose of vilaprisan + midazolam. The second dose of vilaprisan + midazolam was given after a washout period of at least 14 days. The final examination took place within 14 days after the last administration of rifampicin. Safety parameters were monitored throughout the study. PK, pharmacokinetic in plasma were taken at regular intervals. Blood samples for monitoring changes in bilirubin glucuronidation were taken before, during and after treatment with RIF.
The following noncompartmental single dose PK parameters were determined for VPR and MDZ using the software WinNonlin, version 5.3 (Princeton, NJ, USA): AUC, area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t last )], maximum observed plasma concentration (C max ), terminal half-life (t½) and apparent plasma clearance (CL/F). In addition, the following AUC and C max ratios (AUCR and C max R, respectively) were calculated for VPR and MDZ: AUCR = AUC _period 2 /AUC _period 1 ; AUC(0-t last ) R = AUC(0-t last ) _period 2 / AUC(0-t last ) _period 1 ; and C max R = C max_period 2 /C max_period 1 . Further, the metabolite ratio for MDZ, AUC(0-t last ) _1´-OH-MDZ / AUC(0-t last ) _MDZ , was determined for each period, to allow comparisons with historical data.
For bilirubin, the conjugation ratio was calculated for each sampling day.
Safety assessments included adverse events (AEs) and concomitant medications (information obtained by open questioning), standard clinical laboratory tests, vital signs measurements and electrocardiogram (ECG) recordings.
Bioanalytical methods
High-performance liquid chromatography-tandem mass spectrometry methods, which were validated according to the relevant European and US guidelines [15, 16] , were used to determine levels of VPR, MDZ and 1'-OH-MDZ in individual plasma samples. For details and an overview of the performance of the bioanalytical methods, see Appendix.
Levels of total and conjugated bilirubin in the serum were measured using a validated photometric assay. The concentration of unconjugated bilirubin was calculated as the total bilirubin minus conjugated bilirubin concentrations.
Statistical analysis
Statistical analyses were conducted using the software package SAS release 9.2 (SAS Institute Inc., Cary, NC, USA). Additional graphs were prepared using the software SigmaPlot 13.0 (Systat Software Inc., San Jose, CA, USA) or GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA, USA). All data were summarized using descriptive statistics or frequency tables as appropriate.
The impact of RIF on the PK of VPR and MDZ was investigated by performing an analysis of variance (ANOVA; including treatment and subject effects) on the log-transformed AUC, AUC(0-t last ) and C max values of VPR and MDZ. For each ANOVA, the point estimate and 90% confidence interval (CI) for the ratio 'with RIF/without RIF' (or 'period 2/period 1') were calculated by retransforming the point estimate (least squares mean) and 90% CI of the corresponding model to the original scale.
Bilirubin conjugation ratios were calculated for pretreatment with RIF, at five time points during or after treatment with RIF, and for follow-up. A linear mixed model including fixed time point effects and random subject effects, along with Bonferroni-Holm-adjusted multiple comparisons, were applied in order to explore changes in the bilirubin conjugation ratio.
AEs were classified for analysis using MedDRA, version 19.1 (McLean, VA, USA).
A sample size of 10 evaluable subjects was considered to be sufficient to fulfil the objectives of the study. The variability of DDI ratios was estimated using information on PK variability from prior PK studies with VPR (e.g. [8] ) and MDZ [17, 18] and from population PBPK modelling. To account for possible dropouts, 12 subjects were randomized.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [19] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [20] .
Results

Study subjects
In total, 36 women were assessed for eligibility. Twenty-four of these were screening failures; 12 subjects were included and received study medication (safety analysis set). Of these, 11 subjects completed both study periods as planned (PK analysis set). One subject withdrew prematurely owing to an AE prior to having received the second dose of VPR + MDZ. All 12 subjects were Caucasians; their ages ranged from 51 years to 64 years (median: 57.0 years) and their body weights ranged from 55.0 kg to 87.6 kg (median: 71.5 kg). Figure 2 shows that coadministration of RIF was associated with a marked decrease in the concentrations of VPR and MDZ in the plasma. The PK parameters for VPR and MDZ are summarized in Table 1 . The results of the ANOVAs for AUC(0-t last ) of VPR and MDZ (Table 2) indicate that the exposure to VPR was reduced by 96% and the exposure to MDZ by 86% with coadministration of RIF compared with the administration of VPR and MDZ alone. The corresponding C max values were reduced by 86% and 84%, respectively. Figure 3 evaluates the distribution of individual AUC(0-t last ) values of VPR and MDZ in period 1 and their subsequent percentage decreases in period 2. The graphs illustrate that there was less variability observed in the percentage decrease in the exposure to VPR than in the exposure to MDZ. AUC(0-t last ) values were used for all exposure analyses. As plasma concentrations of VPR decreased rapidly below the lower limit of quantitation (LLOQ; 0.05 μg l ) following pretreatment with RIF, the terminal elimination phase (covering at least two elimination half-lives) could not be determined in most subjects. Therefore, total AUC could not be calculated in the majority of subjects. Instead of AUC, AUC(0-t last ) was used for exposure comparison. AUC(0-t last ) and AUC were very similar as plasma concentrations were less than 1/100 of C max during the terminal phase, representing only a marginal exposure fraction.
PK results
Metabolite ratios for MDZ [AUC(0-t last ) _1'-OH-midazolam / AUC(0-t last ) _midazolam ] were similar with and without concomitant RIF (0.371 with RIF and 0.435 without RIF) ( Table 1) . Figure 4 shows the distribution of bilirubin conjugation ratios before, during and after treatment with RIF. Mean conjugation ratios increased at the beginning of treatment with RIF, seemed to reach a plateau after 6 days and decreased again in the week following the end of treatment. However, the interindividual variability was considerable. The increase in the bilirubin conjugation ratio after the start of treatment with RIF is also visible in the results of the linear mixed model applied. The P-values of the pairwise comparisons of the values from all time points after the first dose of RIF with the pretreatment measurement are all ≤0.0628. Specifically, the data from day 6 and day 8 of RIF treatment, as well as the data from the follow-up, are significant at a global significance level of 0.05.
Conjugation of bilirubin
Safety results
VPR + MDZ treatment, with and without RIF treatment, was safe and well tolerated, with no clinically relevant effects on vital signs, ECG or laboratory parameters. In particular, the evaluation of liver enzymes (aspartate transaminase, alanine transaminase, γ-glutamyl transpeptidase, alkaline phosphatase) and total bilirubin did not indicate any influence of (A) (B)
Figure 2
Mean plasma concentration-time profiles for vilaprisan (A) and midazolam (B). Geometric means ± standard deviations (calculated if at least twothirds of the individual values were above the lower limit of quantitation); N = 11. Subjects received a single dose of vilaprisan 4 mg + midazolam 1 mg with and without prior and concomitant administration of rifampicin, 600 mg day -1 . LLOQ, lower limit of quantification; MDZ, midazolam AUC, area under the plasma concentration-time curve from zero to infinity; AUC(0-t last ), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration; C max , maximum observed plasma concentration; CV%, geometric coefficient of variation (%); gMean, geometric mean; min, minimum; max, maximum; N, number of valid cases; t½, terminal half-life; CL/F, apparent plasma clearance of drug after extravascular administration a Metabolite ratio for midazolam = AUC(0-t last ) _1'-OH-midazolam /AUC(0-t last ) _midazolam CYP3A4-and UGT1A1-mediated effects of rifampicin the study medication on the evaluated parameters. The mean values were within the limits of the reference ranges at all time points of assessment. All subjects reported at least one AE. Most of them were mild in intensity and all were resolved at the end of the study. No serious AEs occurred. Most often reported were chromaturia -a known side effect of RIF -and headache (four subjects with VPR + MDZ, one subject with RIF only, five subjects with VPR + MDZ + RIF). One subject discontinued the study after 4 days of treatment with RIF because of nausea, vomiting, abdominal distension, dizziness and headache. Drowsiness -a possible side effect of MDZ -was not an issue.
Discussion
Consistent with our predictions [11] , concomitant treatment with the strong CYP3A4 inducer RIF was associated with a 96% decrease (geometric mean) in exposure [AUC(0-t last )] to VPR in our study. Maximum observed concentrations of VPR in the plasma were reduced by 86%. These findings confirm the key role of CYP3A4 in the metabolism of VPR. CYP3A4 induction was confirmed by a reduction in MDZ exposure in all subjects. Supported by an exposure-response model established in patients [21] , it is predicted that such a decrease in exposure will render VPR clinically ineffective. Thus, due to this loss of efficacy, and not for safety reasons, the use of strong CYP3A4 inducers such as RIF is not recommended with VPR.
A PBPK had previously been developed and successfully used to predict the DDI of VPR with the strong CYP3A4 inhibitor itraconazole [22] . This PBPK model has now also been qualified by predicting the DDI with the strong CYP3A4 inducer RIF. Based on the successful DDI prediction of both a strong CYP3A4 inhibitor and a strong inducer covering the extreme interaction range, this PBPK model will be used in the future to simulate DDI with moderate CYP3A4 inhibitors and inducers, to provide guidance for the coadministration of drugs with a moderate CYP3A4 interaction potential.
In the present study, the model was used to optimize the following treatment and sampling parameters [11] : (i) duration of pretreatment with the perpetrator RIF; (ii) intervals between administration of the 'victim' drugs VPR and MDZ on the one hand, and administration of the perpetrator RIF on the other (to minimize the effects of transient CYP3A4 Terminal half-life and AUC could be determined only in three subjects after coadministration of rifampicin. Therefore, the focus of this analysis was on AUC(0-t last ). AUC, area under plasma concentration-time curve from zero to infinity; AUC(0-t last ), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration; C max , maximum plasma concentration; CV%, geometric coefficient of variation (%); N, number of valid cases Figure 3 Relationship between exposure to vilaprisan or midazolam at baseline and the decrease in exposure to vilaprisan or midazolam, respectively, that occurred with concomitant administration of rifampicin -individual data. A subject is represented with the same symbol in both plots. AUC(0-t last ), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration; baseline, exposure without coadministration of rifampicin; %decrease in AUC(0-t last ) = (AUC(0-t last ) _period 1 -AUC(0-t last ) _period 2 ) /AUC(0-t last ) _period 1 *100 inhibition by RIF); (iii) duration of treatment with RIF after administration of the victim drugs (to maintain CYP induction during VPR exposure); and (iv) selection of a minimum number of blood sampling time points for a full PK profile of VPR and MDZ. Details of the respective simulations will be published in a separate article. Optimization was framed with a maximum duration of treatment with RIF of 14 days owing to the known side effects of RIF [14] . Pretreatment with RIF 600 mg once daily for 1 week was predicted to be sufficient to achieve maximum induction of CYP3A4, and an interval of at least 8 h between administration of the victim drugs and the next dose of RIF was determined to be necessary to minimize the effects of transient competitive CYP3A4 inhibition by RIF [11] . A choice of smaller dosing intervals may blur the maximum induction effect, with a bias of up to fivefold in the AUCR of sensitive CYP3A4 substrates. For practical reasons, it was decided to administer the victim drugs 24 h after the last pretreatment dose of RIF and 12 h before the first posttreatment dose of RIF. Simulations showed that the level of CYP induction reached at the end of the pretreatment period would be reasonably stable during such a 36-h gap in the RIF dosing schedule. Posttreatment with RIF for 3 days was predicted to cover the complete time of exposure to VPR after dosing (24 h for MDZ). Thus, the total duration of treatment with RIF amounted to 11 days and was well below the abovementioned limit of 14 days. Although we could not prove that the proposed minimum difference of 8 h between the dose of a CYP3A4 substrate and the next RIF dose achieves the maximum observable induction, the agreement of predicted and observed results using a 12-h difference clearly supports the contention that prior PBPK evaluations were reliable.
Further, we used our PBPK model to identify the minimum dose of MDZ (1 mg, easily administrable without dilution from marketed oral formulations) that would be sufficient for PK profiling of MDZ and to evaluate the metabolite ratio for MDZ, taking into account the LLOQ (0.002 μg l -1 for MDZ; 0.005 μg l -1 for its metabolite) of the validated analytical methods. Minimization of the MDZ dose was essential to avoid sedation and the other known pharmacological effects of MDZ. We used this well-characterized index substrate [2] as an internal positive control: (ii) for verifying CYP3A4 induction in all study subjects; and (ii) for bridging our DDI data for VPR and MDZ with the results of published DDI studies that investigated other CYP3A4 inducers together with MDZ as CYP3A4 substrate. Inspection of individual exposure data for MDZ confirmed that CYP3A4 was, indeed, induced in all subjects to the expected extent. The overall effect of RIF coadministration on exposure to MDZ -a 86% decrease in AUC(0-t last ) and a 84% decrease in C max -was consistent with our PBPK predictions. A similar change in exposure has also been described by others (e.g. [17, [23] [24] [25] [26] ).
In the present study, on average, it was observed that the RIF-associated decrease in exposure to MDZ was less pronounced than the decrease in exposure to VPR, and that the variability in the effect of RIF on AUC(0-t last ) was lower for VPR than for MDZ (Figure 3 ). VPR and MDZ are similarly sensitive CYP3A4 substrates, with an estimated fraction metabolized by CYP3A4 of >0.9 for both VPR [22] and MDZ [27] . However, there may be differences in the contribution of first-pass metabolic clearance. For MDZ, the intestinal contribution is estimated using intestinal bioavailability (F G ) values of 0.51 [28] and 0.52 [29] based on predictions from in vitro models, and of about 0.57 determined in vivo in anhepatic patients after intraduodenal drug administration [30] or in an interaction study using grapefruit juice as an enzyme inhibitor [31] . By contrast, based on the PBPK model of VPR, an F G value of 0.65 has been estimated for VPR, which is consistent with an estimated F G value of 0.66 derived from an absolute bioavailability study [9] , assuming a well-stirred liver model with a liver blood flow of 25.5 ml min -1 kg -1 [32] and complete oral absorption. The hepatic bioavailability (F H ) for VPR is estimated to be 0.93, which is also higher than that of MDZ, which has an F H of about 0.57 [33] . The net effect of these differences is that the oral bioavailability of VPR, at 61% [9] , is higher than the mean oral bioavailability reported for MDZ (approximately 40-52%) [34, 35] . Thus, first-pass metabolism appears to be more pronounced for MDZ than for VPR, which may also explain the lower interindividual variability in the decrease in exposure for VPR. To our knowledge, the time course of changes in the extent of bilirubin glucuronidation on starting treatment with multiple doses of RIF has not been reported previously. Increased bilirubin glucuronidation has been inferred in patients with UGT1A1 deficiency (Gilbert's syndrome) who had symptomatic relief from hyperbilirubinaemia on being treated with RIF [36] . UGT1A1 inhibitors can have a reverse effect; Sane et al. hypothesized that reversible, unconjugated hyperbilirubinaemia associated with faldaprevir may predominantly result from inhibition of bilirubin glucuronidation [37] . In our study, we observed a trend towards increasing glucuronidation of bilirubin during treatment with RIF. Interestingly, glucuronidation ratios were also
Figure 4
Ratios of conjugated bilirubin to unconjugated bilirubin: Box-andwhisker plot. Asterisks indicate statistically significant differences vs. baseline at a global significance level of 0.05 (linear mixed model with fixed time point and random subject effects, along with Bonferroni-Holm adjusted P-values); N = 11. MDZ, midazolam 1 mg; RIF, rifampicin 600 mg day -1 ; VPR, vilaprisan 4 mg statistically significantly higher at the follow-up visit (any time within 14 days after the last dose of RIF), indicating that UGT1A1 activity levels may not have returned to baseline yet, or alternatively that they could have been influenced by lifestyle factors [38, 39] which were not controlled in the period between end of PK sampling and the follow-up visit. The data suggest that our dosing schedule for RIF might also be suitable for DDI studies with UGT1A1 substrates and RIF as a UGT1A1 inducer, although UGT1A1 metabolism was not explicitly included in the model. The current PBPK model for RIF could be extended to include UGT1A1 induction, to investigate this further, provided that the necessary data are available.
The observation of UGT1A1 induction with RIF, as indicated by the increase in bilirubin glucuronidation, in line with the fact that we observed hardly any RIF-associated changes in the metabolite/parent ratio for MDZ. This observation is in agreement with the literature [17, 18] and has been attributed to an increase in the clearance of 1'-OH-MDZ, by assuming the induction of several UGTs involved in the glucuronidation of 1'-OH-MDZ, including UGT1A4, UGT2B4 or UGT2B7, in addition to UGT1A1 [40, 41] . As it is not possible to differentiate between the effects of CYP3A4 and UGT induction, the monitoring of 1'-OH-MDZ does not provide any additional value for the objective of the present study and is not necessary for future DDI studies.
One limitation of the present study was the small sample size; this same size was adequate for the primary objective of the study but allowed only a brief glance at the supplementary question of the effects of RIF on the glucuronidation of bilirubin. In the future, it will be interesting to assess the impact of UGT1A1 induction, and thereby changes in bilirubin glucuronidation, using various dose strengths of RIF. Gaining further understanding of such an endogenous marker could have practical value as there is currently no sensitive exogenous UGT1A1 substrate for routine clinical evaluation.
Conclusion
Consistent with our predictions [11] , a 96% decrease [AUC(0-t last )] in exposure to VPR was observed when RIF was coadministered according to an administration schedule designed for maximum induction of CYP3A4. A decrease in drug exposure of this magnitude will render the drug therapeutically ineffective. Therefore, it is recommended that the use of strong CYP3A4 inducers when taking VPR is avoided.
The greater decrease in exposure to VPR compared with MDZ indicates that the contribution of CYP3A4 to the total plasma clearance for VPR is even higher than for MDZ. Further, there was less variability observed in the percentage decrease in exposure for VPR than for MDZ. This could perhaps be explained by the lower contribution of first-pass clearance by CYP3A4 for VPR than for MDZ. 
